This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID WARFARIN

Stroke, Vol 21, 538-545, Copyright © 1990 by American Heart Association

ARTICLES

Design of a multicenter randomized trial for the Stroke Prevention in Atrial Fibrillation Study. The Stroke Prevention in Atrial Fibrillation Investigators

Individuals with nonvalvular atrial fibrillation are at increased risk of stroke. The Stroke Prevention in Atrial Fibrillation Study is a 15- center randomized clinical trial examining the risks and benefits of low-intensity warfarin (prothrombin time of 1.3-1.8 times control) and aspirin (325 mg/day) in patients with constant or intermittent atrial fibrillation. Candidates for anticoagulation (group I) are randomized to receive warfarin in an open-label fashion, aspirin, or placebo; the last two treatments are given in a double-blind fashion. Warfarin- ineligible patients (group II) are randomized to receive aspirin or placebo in a double-blind fashion. Primary end points are ischemic stroke and systemic embolism. Secondary end points are death, transient ischemic attack, myocardial infarction, and unstable angina pectoris. Analysis is based on the intention-to-treat principle. The anticipated rate of primary end points in patients receiving placebo is 6%/yr. The sample size of 1,644 patients is based on a projected reduction in the rate of primary end points of 50% by warfarin and of 33% by aspirin (beta = 0.2, alpha = 0.05). Patient entry commenced in June 1987 and will continue for 3 years, with an additional year of follow-up. High- risk subsamples identified by clinical and echocardiographic criteria are sought prospectively.

This article has been cited by other articles:

				V. F. Tapson, T. M. Hyers, A. L. Waldo, D. J. Ballard, R. C. Becker, J. A. Caprini, R. Khetan, A. K. Wittkowsky, K. J. Colgan, A. C. Shillington, et al. Antithrombotic Therapy Practices in US Hospitals in an Era of Practice Guidelines Arch Intern Med, July 11, 2005; 165(13): 1458 - 1464. [Abstract] [Full Text] [PDF]

				M.J. Ariesen, A. Algra, P.J. Koudstaal, P.M. Rothwell, C. van Walraven, and for the AFASAK, DTT, EAFT, PATAF, SPAF, SPIRIT, an Risk of Intracerebral Hemorrhage in Patients With Arterial Versus Cardiac Origin of Cerebral Ischemia on Aspirin or Placebo: Analysis of Individual Patient Data From 9 Trials Stroke, March 1, 2004; 35(3): 710 - 714. [Abstract] [Full Text] [PDF]

				R. G. Hart, J. L. Halperin, L. A. Pearce, D. C. Anderson, R. A. Kronmal, R. McBride, E. Nasco, D. G. Sherman, R. L. Talbert, J. R. Marler, et al. Lessons from the Stroke Prevention in Atrial Fibrillation Trials Ann Intern Med, May 20, 2003; 138(10): 831 - 838. [Abstract] [Full Text] [PDF]

				D.C. Anderson, L.J. Kappelle, M. Eliasziw, V.L. Babikian, L.A. Pearce, H.J.M. Barnett, and J. Blakely Occurrence of Hemispheric and Retinal Ischemia in Atrial Fibrillation Compared With Carotid Stenosis * Editorial Comment Stroke, August 1, 2002; 33(8): 1963 - 1968. [Abstract] [Full Text] [PDF]

				B. J. Quilliam, K. L. Lapane, and C. Leibson Clinical Correlates and Drug Treatment of Residents With Stroke in Long-Term Care Editorial Comment Stroke, June 1, 2001; 32(6): 1385 - 1393. [Abstract] [Full Text] [PDF]

				M. D. Ezekowitz and J. A. Levine Preventing Stroke in Patients With Atrial Fibrillation JAMA, May 19, 1999; 281(19): 1830 - 1835. [Abstract] [Full Text] [PDF]

				T. Nagao, M. Hamamoto, A. Kanda, T. Tsuganesawa, M. Ueda, K. Kobayashi, T. Miyazaki, and A. Terashi Platelet Activation Is Not Involved in Acceleration of the Coagulation System in Acute Cardioembolic Stroke With Nonvalvular Atrial Fibrillation Stroke, August 1, 1995; 26(8): 1365 - 1368. [Abstract] [Full Text]

				Antiplatelet Trialists Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ, January 8, 1994; 308(6921): 81 - 106. [Abstract] [Full Text]